18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma
Frontiers in Oncology · 24.08.2026 · 16
DOI: 10.3389/fonc.2026.1856758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.08.2026. Verfasst von Jinhai Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common and highly heterogeneous subtype of non-Hodgkin lymphoma, and accurate staging is essential for treatment planning and prognosis. This study explored the value of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) metabolic network connectivity for the clinical staging of DLBCL.
Methods
Forty-two previously untreated patients (23 males, 19 females; aged 30-82 years) diagnosed as de novo DLBCL, not otherwise specified, were retrospectively analyzed (stage I, n=3; II, n=5; III, n=9; IV, n=25). Lesions were automatically delineated using a 41% SUVmax threshold. Four metabolic and four diffusion parameters were computed, and a radiomics-based lesion metabolic network was constructed for each patient with stage II-IV disease.
Results
The degree Pearson correlation coefficient (DPCC) of the metabolic network differed significantly among stages II-IV (n=39, p<0.001) and between stage II (n=5) and stages III+IV (n=34) (p<0.001), whereas conventional metabolic, diffusion, and other network parameters showed no significant differences. DPCC decreased with increasing stage, indicating rising inter-lesion metabolic heterogeneity.
Discussion
The DPCC of 18F-FDG PET/CT metabolic network connectivity is associated with clinical stage in DLBCL patients with multiple measurable lesions and may provide complementary network-level information. These exploratory findings require external validation in larger, multicenter cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, China.
- Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
- Department of Gastroenterology III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Zitieren
APA
Zou, J., Zou, H., Liu, C., Liang, C., Liang, Y., Zheng, M., & Li, C. (2026). 18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1856758
Vancouver
Zou J, Zou H, Liu C, Liang C, Liang Y, Zheng M, et al. 18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1856758
BibTeX
@article{Zou2026,
author = {Zou, Jinhai and Zou, Han and Liu, Chang and Liang, Chen and Liang, Yufei and Zheng, Meiyu and Li, Chunying},
title = {18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1856758}
}
EUVIMED